A Study to Evaluate the Definitive Bioequivalence of Tedizolid Phosphate Single-Unit-Dose Sachet Powder for Oral Suspension Compared to Tedizolid Phosphate Powder for Oral Suspension Bottle Used in Pediatric Clinical Studies

The goal of the study is to learn what happens to different oral formulations of tedizolid phosphate (MK-1986) in a healthy person's body over time. Researchers want to know if there is a difference in the oral formulations absorption and elimination from the healthy persons body.

开始日期2024-07-16

申办/合作机构

Merck Sharp & Dohme LLC

CTR20242122

/ CompletedN/A

一项随机、开放、两序列交叉设计，评价健康成人空腹/餐后状态下单次口服磷酸特地唑胺片的生物等效性试验

主要目的：考察中国健康受试者在空腹/餐后条件下单剂量口服浙江东亚药业股份有限公司生产的磷酸特地唑胺片（规格：200mg）与持证商为 MSD Pharma(Singapore) Pte Ltd生产厂家为Patheon Inc.的磷酸特地唑胺片（商品名：SIVEXTRO®；规格：200mg）后的体内药代动力学特征，评价两制剂的生物等效性。次要目的：评价单剂量口服磷酸特地唑胺片受试制剂（规格：200mg）及参比制剂（商品名：SIVEXTRO®；规格：200mg）在中国健康受试者中的安全性。

开始日期2024-06-11

申办/合作机构

浙江东亚药业股份有限公司

CTRI/2023/12/060921

/ Completed临床3期

A Phase III, Prospective, Randomized, Double Blind, Double Dummy, Active Controlled, Comparative, Parallel Group, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Tedizolid Tablets 200 mg Versus Linezolid Tablets 600 mg in Adult Patients for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). - NIL

开始日期2024-01-02

申办/合作机构

Exemed Pharmaceuticals

100 项与磷酸特地唑胺相关的临床结果

登录后查看更多信息

100 项与磷酸特地唑胺相关的转化医学

登录后查看更多信息

100 项与磷酸特地唑胺相关的专利（医药）

登录后查看更多信息

1,522

项与磷酸特地唑胺相关的文献（医药）

2025-11-12·mBio

Effect of antibiotics on Kupffer cell immunometabolism relative to intracellular killing of S. aureus using NAD(P)H fluorescence lifetime imaging

Article

作者: Wong-Beringer, Annie ; Beadell, Brent

ABSTRACT:

Staphylococcus aureus bacteremia (SAB) remains a significant clinical burden with high mortality rates. Kupffer cells (KCs) are integral to clearing Staphylococcus aureus (SA) from the bloodstream yet also serve as a pathogenic reservoir, driving persistence and treatment failure. KCs utilize their metabolic plasticity to coordinate successful antimicrobial responses, and this process may be therapeutically targeted. We investigated the immunometabolic effects of antistaphylococcal antibiotics (vancomycin, ceftobiprole, daptomycin, and tedizolid) on KCs relative to clearance of intracellular SA through gene expression analysis and optical metabolic imaging using fluorescence lifetime imaging microscopy. We observed differential effects of antibiotics on KC polarization and metabolic signatures, with ceftobiprole inducing the strongest pro-inflammatory M1 expression profile and shortest mean NAD(P)H fluorescence lifetime in KCs in the absence of infection, and a retained M1 expression profile but longest NAD(P)H lifetime during infection. Daptomycin and tedizolid most effectively cleared intracellular SA, induced significantly longer NAD(P)H lifetimes, and exhibited decreased M1 gene expression. Vancomycin failed to control intracellular infection showing blunted M1 expression without altering NAD(P)H lifetimes. Stratification of NAD(P)H lifetime signals revealed daptomycin significantly increased binding to PDH-like enzymes and nitric oxide synthase 2 compared to other antibiotics. These findings reveal novel insights into antibiotic modulation of KC immunometabolism during SA infection, which may influence treatment outcomes in SAB.

IMPORTANCE:

Staphylococcus aureus bloodstream infection is a leading cause of sepsis and is associated with up to 30% mortality. Despite treatment with guideline-recommended antibiotics, persistent bacteremia develops in one in three patients, which may be attributed in part to survival of bacteria inside liver-resident macrophages known as KCs. Using gene expression and optical metabolic profiling, we demonstrated that antistaphylococcal antibiotics differentially affect KC metabolism and function, thereby contributing to the overall killing of intracellular bacteria. Daptomycin, ceftobiprole, and tedizolid exert distinct effects on KC metabolism that correspond to effective intracellular killing and prompt resolution of inflammatory response. Vancomycin, however, did not affect KC metabolism and was unable to control bacterial growth inside the cells. These findings suggest that choosing antibiotics based on direct antimicrobial activity as well as indirect effects on host immune function could improve treatment outcomes for patients with S. aureus bloodstream infection.

2025-11-04·JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series

Article

作者: Vieux, Noémie ; Chaudier, Philippe ; Mojallal, Alain-Ali ; Stacoffe, Nicolas ; Chauvelot, Pierre ; Druel, Thibault ; Beringheli, Tomaso ; Maucotel, Anne-Lise ; Landre, Sophie ; Couraudon, Alexandre ; Cotte, Matthieu ; Macabéo, Caroline ; Dupieux, Céline ; Walch, Arnaud ; Aubrun, Frédéric ; Martres, Sébastien ; Cuinet, Thomas ; Gaillard, Christophe ; Batailler, Cécile ; Boulant, Johanna ; Garreau, Romain ; Vervust, Grégoire ; Bertani, Antoine ; Curtil-Dit-Galin, Matthieu ; Fessy, Michel ; Derreveaux, Vianney ; Pialat, Jean-Baptiste ; Ben-Hadid, Nael ; Pibarot, Vincent ; Simon, Marie ; Van-Den-Bogaart, Lorena ; Rutka, Victor ; Trouillet, Franck ; Horikian, Ani ; Cottin, Judith ; Ader, Florence ; Vanpoulle, Gaetan ; Cance, Nicolas ; Lavigne, Joris ; Viste, Anthony ; Gazarian, Aram ; Javaux, Clément ; Triffault-Filit, Claire ; Ewald, Fabien ; Hashim, Abdulrahman ; Rarchaert, Maxime ; Colas, Antoine ; Morelec, Isabelle ; Servien, Elvire ; Besse, Jean-Luc ; Ducharne, Louis ; Lahlali, Selma ; Lippman, Joanna-Isabelle Kurban Bessa ; Braun, Evelyne ; Briot, Thomas ; Roux, Sandrine ; Lustig, Sébastien ; Perpoint, Thomas ; Lherm, Mathilde ; Chevreau-Ciliberti, Audrey ; Rasigade, Jean-Philippe ; Gicquel, David ; Roussel-Gaillard, Tiphaine ; Rouhana, Kaissar ; Eberl, Isabelle ; Vézole, Léonard ; Bahuaud, Olivier ; Wan, Marie ; Person, Hélène ; Delfosse, Gerald ; Ly, Lyliane ; Gunst, Stanislas ; Goutelle, Sylvain ; Masson, Jean-Baptiste ; Trecourt, Alexis ; Mesnard, Guillaume ; Henry, Guillaume ; Rongieras, Frédéric ; Becker, Agathe ; Kolenda, Camille ; Beraud, Laetitia ; Erard, Julien ; Conrad, Anne ; Baltzer, Jean ; Ferry, Tristan ; Soueges, Sarah ; Valour, Florent ; Dziadzko, Mikhail ; Henry, Agnes

Abstract:

Background and objectives:

Due to its potentially better long-term haematologic tolerance compared to linezolid, tedizolid represents an attractive option for prolonged antibiotic therapy in complicated/chronic Gram-positive infections. However, there is little information regarding the risk of peripheral neurological toxicity, representing another obstacle to the extended use of oxazolidinones. Reporting neurologic adverse events occurring during tedizolid therapy for chronic implant-associated infections.

Patients and methods:

Patients experiencing tedizolid-associated neurologic adverse events were retrospectively described in a case series.

Results:

Five patients (four males; age range, 65–75 years) receiving tedizolid (200 mg q24h) as long-term suppressive therapy for chronic implant-associated infection presented with peripheral neuropathy. In four cases, tedizolid was used after discontinuation of linezolid for toxicity, including one case of neuropathy. Three had at least one additional risk factor for neuropathy (including two diabetes, one of them with diabetes-related nephropathy). Neuropathic symptoms [paraesthesia (n = 2), worsening of pre-existing neuropathy (n = 2), dysesthesias (n = 1)] appeared after a median of 12.4 (IQR, 8.2–13.3) months of tedizolid treatment. Electromyoneurography (EMNG) confirmed axonal sensory polyneuropathy in all but one patient for which EMNG was still within normal ranges, but compatible with incipient neurotoxicity. Tedizolid was stopped in all patients, three patients required specific treatment for neuropathic pain. At last follow-up [2.4 (IQR, 1–2.5) years from tedizolid discontinuation], clinical recovery from neuropathy was noted in three patients. The two patients with persistent neuropathy symptoms were diabetic; one showed EMNG improvement.

Conclusions:

Prolonged used of tedizolid may be associated with peripheral neurologic toxicity, which should be monitored in at-risk patients.

2025-10-08·CURRENT CANCER DRUG TARGETS

Zinc-Facilitated Enzyme Disruption: Thiazolidinediones as Potent Carbonic Anhydrase Inhibitors in Hypoxic Cancer Microenvironments

Article

作者: Sunita, Priyashree ; Pattanayak, Shakti Prasad ; Ranjan, Gaurav

Introduction::

Thiazolidinedione (TZD) derivatives have gained significant atten-tion as anti-cancer agents due to their diverse biological activities. The objective of the re-search was to investigate the potential of thiazolidine derivatives as inhibitors of Carbonic anhydrase XII, an isoform overexpressed in hypoxic tumor environments, to explore their ap-plication as anticancer agents targeting breast cancer.

Methods::

The study employed a computational approach to evaluate thiazolidine derivatives as potential CA XII inhibitors. Acute toxicity and safety were evaluated using ProTox 3.0. Molecular docking was conducted to study interactions with the zinc-bound active site of CA XII. Molecular dynamics simulations were performed to validate the stability of the ligand-enzyme complex over 250 ns.

Results::

TZD derivatives demonstrated favorable physicochemical properties, high gastroin-testinal absorption, and low toxicity risks. Molecular docking studies showed strong binding affinities with key hydrogen bonding and zinc coordination at the CA XII active site. Toxicity predictions indicated that most compounds had acceptable safety margins, reinforcing their potential as safe and effective CA XII inhibitors.

Discussion::

The findings suggest that thiazolidine scaffolds could serve as promising small-molecule inhibitors of CA XII by targeting its zinc-bound catalytic site, a mechanism con-sistent with previously reported CA inhibitor pharmacology.

Conclusion::

The study demonstrates that TZD derivatives possess promising characteristics as CA XII inhibitors, with favorable physicochemical properties, strong binding affinity, stable ligand-protein interactions, and acceptable safety profiles. These findings highlight their po-tential for further in vitro and in vivo validation, supporting the continued exploration of thia-zolidinedione scaffolds in the development of targeted anticancer therapies.

237

项与磷酸特地唑胺相关的新闻（医药）

2025-11-23

·信狐药迅

全球首创双抗ADC：成都百利多特BL-B01D1提交上市申请|新受理（11.17-11.23）

本周药品注册受理数据，分门别类呈现，一目了然。(11.17-11.23）新药上市申请药品名称企业注册分类受理号氢溴酸伏硫西汀口崩片深圳市泛谷药业股份有限公司 2.2 CXHS2500138 氢溴酸伏硫西汀口崩片深圳市泛谷药业股份有限公司 2.2 CXHS2500137 硫酸艾玛昔替尼片江苏恒瑞医药股份有限公司 2.4 CXHS2500141 芦沃美替尼片上海复星医药产业发展有限公司 2.4 CXHS2500140 芦沃美替尼片上海复星医药产业发展有限公司 2.4 CXHS2500139 注射用BL-B01D1 成都百利多特生物药业有限责任公司 1 CXSS2500124 新药临床申请药品名称企业注册分类受理号 HYP-6589片四川汇宇海玥医药科技有限公司 1 CXHL2501289 HYP-6589片四川汇宇海玥医药科技有限公司 1 CXHL2501288 BPI-572270胶囊杭州景曜生物科技有限责任公司 1 CXHL2501287 BPI-572270胶囊杭州景曜生物科技有限责任公司 1 CXHL2501286 BPI-572270胶囊杭州景曜生物科技有限责任公司 1 CXHL2501285 BPI-572270胶囊杭州景曜生物科技有限责任公司 1 CXHL2501284 CKBA乳膏江苏博创园生物医药科技有限公司 1 CXHL2501282 CKBA乳膏江苏博创园生物医药科技有限公司 1 CXHL2501281 CKBA乳膏江苏博创园生物医药科技有限公司 1 CXHL2501280 ASP3082注射液安斯泰来(中国)投资有限公司 1 CXHL2501279 RAY1225注射液广东众生睿创生物科技有限公司 1 CXHL2501278 RAY1225注射液广东众生睿创生物科技有限公司 1 CXHL2501277 RAY1225注射液广东众生睿创生物科技有限公司 1 CXHL2501276 RAY1225注射液广东众生睿创生物科技有限公司 1 CXHL2501275 RAY1225注射液广东众生睿创生物科技有限公司 1 CXHL2501274 HSK42360-Na片海思科医药集团股份有限公司 1 CXHL2501283 PAN-90806滴眼液兆科(广州)眼科药物有限公司 1 CXHL2501270 BG-75098片百济神州(苏州)生物科技有限公司 1 CXHL2501273 BG-75098片百济神州(苏州)生物科技有限公司 1 CXHL2501272 BG-75098片百济神州(苏州)生物科技有限公司 1 CXHL2501271 TQF3250胶囊正大天晴药业集团股份有限公司 1 CXHL2501268 TQF3250胶囊正大天晴药业集团股份有限公司 1 CXHL2501267 TQF3250胶囊正大天晴药业集团股份有限公司 1 CXHL2501266 IJ-25-362片成都茵创园医药科技有限公司 1 CXHL2501265 YKYY032注射液北京悦康科创医药科技股份有限公司 1 CXHL2501263 AP-2202片杭州安元生物医药科技有限公司 2.1;2.4 CXHL2501262 YKRH00257吸入溶液北京盈科瑞创新药物研究有限公司 2.2 CXHL2501264 氨氯地平双叶酸片深圳奥萨制药有限公司 2.3 CXHL2501269 重组三价流感病毒疫苗(Sf9细胞) 成都威斯克生物医药有限公司 1.3 CXSL2500983 重组三价流感病毒疫苗(Sf9细胞) 成都威斯克生物医药有限公司 1.3 CXSL2500982 重组带状疱疹ZFA01佐剂疫苗(CHO细胞) 安徽智飞龙科马生物制药有限公司 1.3 CXSL2500978 流感病毒裂解疫苗(高剂量) 成大生物(本溪)有限公司 3.2 CXSL2500998 注射用LM-24C5 礼新医药科技(上海)有限公司 1 CXSL2500999 QLP2117注射液齐鲁制药有限公司 1 CXSL2500993 注射用SKB518 四川科伦博泰生物医药股份有限公司 1 CXSL2500997 注射用HLX43 上海复宏汉霖生物技术股份有限公司 1 CXSL2500996 重组抗EGFR人源化单抗注射液上海复宏瑞霖生物技术有限公司 1 CXSL2500995 注射用JSKN003 江苏康宁杰瑞生物制药有限公司 1 CXSL2500994 SHR-1894注射液苏州盛迪亚生物医药有限公司 1 CXSL2500990 SYS6010 石药集团巨石生物制药有限公司 1 CXSL2500988 EHT102注射液上海佑音医药生物科技有限公司 1 CXSL2500989 YSC001注射液演生潮(北京)生物科技有限公司 1 CXSL2500984 ZL-1503注射液再鼎医药(上海)有限公司 1 CXSL2500981 JH021注射液百泰生物药业有限公司 1 CXSL2500987 注射用DB-1311 映恩生物制药(苏州)有限公司 1 CXSL2500986 Pumitamig注射液百时美施贵宝(中国)投资有限公司 1 CXSL2500985 注射用ZG005 苏州泽璟生物制药股份有限公司 1 CXSL2500975 RGL-270注射液上海瑞宏迪医药有限公司 1 CXSL2500980 XW003注射液杭州先为达生物科技股份有限公司 1 CXSL2500977 XW003注射液杭州先为达生物科技股份有限公司 1 CXSL2500976 JNJ-95597528注射液强生(中国)投资有限公司 1 CXSL2500974 QL2107注射液齐鲁制药有限公司 2.2 CXSL2500992 阿得贝利单抗注射液上海盛迪医药有限公司 2.2 CXSL2500979 仿制药申请药品名称企业注册分类受理号右酮洛芬氨丁三醇注射液山东达冠医药科技有限公司 3 CYHS2504037 地氯雷他定口服溶液广东南国药业有限公司 3 CYHS2504035 注射用氨磷汀大连美罗中药厂有限公司 3 CYHS2504020 氨溴特罗口服溶液中山可可康制药有限公司 3 CYHS2504012 利格列汀二甲双胍缓释片(I) 江苏德源药业股份有限公司 3 CYHS2504008 托伐普坦口崩片天津力生制药股份有限公司 3 CYHS2504007 二甲磺酸利右苯丙胺胶囊宜昌人福药业有限责任公司 3 CYHS2504006 托伐普坦口崩片天津力生制药股份有限公司 3 CYHS2504005 二甲磺酸利右苯丙胺胶囊宜昌人福药业有限责任公司 3 CYHS2504004 二甲磺酸利右苯丙胺胶囊宜昌人福药业有限责任公司 3 CYHS2504003 甘油果糖氯化钠注射液广东大翔制药有限公司 3 CYHS2504002 二甲磺酸利右苯丙胺胶囊宜昌人福药业有限责任公司 3 CYHS2504001 甘油果糖氯化钠注射液广东大翔制药有限公司 3 CYHS2504000 小儿复方氨基酸注射液(20AA) 远大医学营养科学(武汉)有限公司 3 CYHS2503999 复方聚乙二醇(3350)电解质散上海朝晖药业有限公司 3 CYHS2503991 复方聚乙二醇(3350)电解质口服溶液杭州民生药物研究院有限公司 3 CYHS2503990 注射用青霉素钠/氯化钠注射液湖南科伦制药有限公司 3 CYHS2503986 注射用青霉素钠/氯化钠注射液湖南科伦制药有限公司 3 CYHS2503985 依巴斯汀口服溶液杭州民生药物研究院有限公司 3 CYHS2503982 布洛芬颗粒吉林开曼药业有限公司 3 CYHS2503977 布洛芬颗粒吉林开曼药业有限公司 3 CYHS2503976 磷酸奥司他韦颗粒海南海神同洲制药有限公司 3 CYHS2503975 盐酸丁螺环酮片四川美大康华康药业有限公司 3 CYHS2503974 呋塞米口服溶液亚宝药业四川制药有限公司 3 CYHS2503973 呋塞米口服溶液亚宝药业四川制药有限公司 3 CYHS2503972 酮咯酸氨丁三醇片江苏和晨药业有限公司 3 CYHS2503994 硫酸特布他林口服溶液武汉益博元医药科技有限公司 3 CYHS2503992 苯磺酸美洛加巴林片九华华源药业(桂林)有限公司 4 CYHS2504041 碘佛醇注射液福建森福润医药科技有限公司 4 CYHS2504040 达格列净二甲双胍缓释片(I) 阿斯利康药业(中国)有限公司 4 CYHS2504039 阿司匹林肠溶片悦康药业集团股份有限公司 4 CYHS2504036 氧(液态) 伊犁鸿瑞坤源气体有限公司 4 CYHS2504034 注射用吗替麦考酚酯石家庄四药有限公司 4 CYHS2504038 枸橼酸西地那非片江苏万高药业股份有限公司 4 CYHS2504026 枸橼酸西地那非片江苏万高药业股份有限公司 4 CYHS2504025 盐酸氮卓斯汀鼻喷雾剂四川普锐特药业有限公司 4 CYHS2504030 艾拉莫德片河南诺美药业有限公司 4 CYHS2504029 乌帕替尼缓释片九华华源药业(桂林)有限公司 4 CYHS2504028 伊班膦酸钠注射液山东简道制药有限公司 4 CYHS2504027 达格列净二甲双胍缓释片(III) 合肥立方制药股份有限公司 4 CYHS2504024 达格列净二甲双胍缓释片(II) 合肥立方制药股份有限公司 4 CYHS2504023 达格列净二甲双胍缓释片(I) 合肥立方制药股份有限公司 4 CYHS2504022 苹果酸奈诺沙星氯化钠注射液河北仁合益康药业有限公司 4 CYHS2504021 复方氨基酸注射液(18AA-IX) 武汉市小铂生物科技有限公司 4 CYHS2504033 沙库巴曲缬沙坦钠片四川依科制药有限公司 4 CYHS2504032 沙库巴曲缬沙坦钠片四川依科制药有限公司 4 CYHS2504031 多索茶碱注射液安徽双鹤药业有限责任公司 4 CYHS2504015 盐酸艾司洛尔注射液楚雄和创药业有限责任公司 4 CYHS2504014 硫酸镁钠钾口服用浓溶液成都亚中生物制药有限责任公司 4 CYHS2504013 盐酸氨溴索口服溶液石家庄凯达生物工程有限公司 4 CYHS2504011 聚乙烯醇滴眼液湖北民康药业集团有限公司 4 CYHS2504019 氯雷他定糖浆安徽杰玺医药有限公司 4 CYHS2504018 氯雷他定糖浆安徽杰玺医药有限公司 4 CYHS2504017 利多卡因凝胶贴膏乐明药业(苏州)有限公司 4 CYHS2503998 氧(液态) 渭南陕鼓气体有限公司 4 CYHS2504010 洛索洛芬钠片大桐制药(中国)有限责任公司 4 CYHS2504009 注射用醋酸曲普瑞林齐鲁制药有限公司 4 CYHS2504016 二甲硅油乳剂合肥康惠医药技术有限公司 4 CYHS2503989 二甲硅油乳剂合肥康惠医药技术有限公司 4 CYHS2503988 聚乙烯醇滴眼液四川禾亿制药有限公司 4 CYHS2503987 乳果糖口服溶液江西药都仁和制药有限公司 4 CYHS2503984 注射用磷酸特地唑胺湖南明瑞制药股份有限公司 4 CYHS2503983 厄贝沙坦片翎耀生物科技(上海)有限公司 4 CYHS2503981 达格列净片江苏亚邦爱普森药业有限公司 4 CYHS2503980 达格列净片江苏亚邦爱普森药业有限公司 4 CYHS2503979 聚乙烯醇滴眼液成都普什制药有限公司 4 CYHS2503978 盐酸阿莫罗芬搽剂海南诚锐生物科技有限公司 4 CYHS2503997 阿托伐他汀钙片四川依科制药有限公司 4 CYHS2503996 阿托伐他汀钙片四川依科制药有限公司 4 CYHS2503995 非那雄胺喷雾剂科笛生物医药(无锡)有限公司 4 CYHS2503993 注射用重组人凝血因子VIII 远大蜀阳生命科学(成都)有限公司 3.4 CXSS2500125 环孢素滴眼液(II) 北京汇恩兰德制药股份有限公司 3 CYHL2500206 尿素[14C]胶囊无锡贝塔医药科技有限公司 3 CYHL2500205 水痘减毒活疫苗云南沃森生物技术股份有限公司 3.3 CXSL2500991 进口申请药品名称企业注册分类受理号盐酸伊可白滞素片 Janssen-Cilag International NV 1 JXHS2500133 Omecamtiv Mecarbil缓释片 Cytokinetics, Incorporated 1 JXHL2500362 Omecamtiv Mecarbil缓释片 Cytokinetics, Incorporated 1 JXHL2500361 Omecamtiv Mecarbil缓释片 Cytokinetics, Incorporated 1 JXHL2500360 AMO959硬胶囊 Novartis Pharma AG 1 JXHL2500359 AMO959硬胶囊 Novartis Pharma AG 1 JXHL2500357 Zasocitinib (TAK-279) 胶囊 Takeda Development Center Americas, Inc. 1 JXHL2500355 镥(177Lu)vipivotide tetraxetan注射液 Novartis Pharma AG 2.4 JXHL2500358 用于制备放射性药物镓(68Ga)gozetotide注射液的药盒 Novartis Europharm Limited 5.1 JXHL2500356 Itepekimab注射液 Sanofi-Aventis Recherche & Developpement 1 JXSL2500224 中药相关申请药品名称企业注册分类受理号湿润烧伤膏汕头市美宝制药有限公司 2.3 CXZL2500117 注：绿色字体部分为潜在首仿品种；微信关键词回复 ” 每月药讯：回复年+月，如202509” 获得最新药迅！不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

抗体药物偶联物申请上市

2025-11-21

·药闻纵横

派格生物首个产品获批上市，GLP-1赛道已有16个玩家

11月14日，国家药监局官方网站发布消息，派格生物（02565）自主研发的维培那肽注射液（商品名：派达康）正式获得上市许可，该药物主要针对成人2型糖尿病患者的血糖管理问题。今年早些时候，即5月，派格生物成功在香港联合交易所挂牌上市，而在此之前，该公司曾有过一次冲击资本市场的尝试，但未能如愿。回溯至2021年8月，派格生物向科创板提交了招股说明书，意图筹集约25.38亿元资金，然而在经过两轮详尽的问询后，公司于次年决定撤回申请。从财务表现来看，派格生物在过去几年中持续面临亏损挑战。具体而言，2023年至2025年上半年期间，公司分别记录了2.79亿元、2.83亿元及9362万元的亏损。维培那肽注射液的获批，标志着派格生物迎来了首个商业化产品。公司曾在招股说明书中强调，未来几年的业务发展、财务状况、经营成果及市场前景，将高度依赖于该产品的成功上市与市场表现。据《每日经济新闻》记者深入调查，尽管-1类药物市场展现出巨大的增长潜力，但竞争环境却异常残酷。摩根士丹利研究团队的一份最新报告指出，诺和诺德与礼来在-1类“减肥药物”领域继续保持着领先地位，两者共同占据了高达84%的市场份额。根据派格生物的招股资料，在中国及美国市场，基于-1机制的2型糖尿病及/或肥胖症治疗方案种类繁多，包括艾塞那肽、利拉鲁肽等多种药物。值得注意的是，截至2025年2月底，中国市场上已有16种-1受体激动剂获得批准，同时，超过20种同类候选药物正处于2型糖尿病治疗的临床试验阶段，预示着该领域的竞争将进一步加剧。公司背景：F+轮融资后估值达40亿元派格生物成立于2008年5月13日，是一家专注于自主研究及开发慢性病创新疗法（主要为肽和小分子药物）的生物技术公司，重点关注代谢紊乱领域。目前，PB-119是派格生物的核心产品，同时也是其最接近商业化的药品，主要用于T2DM及肥胖症一线治疗。派格生物的股权结构较为分散。截至最后实际可行日期，该公司第一大股东为Michael Min XU，持有该公司约15.84%的股权份额，并与其一致行动人徐宇虹、Xiangjun ZHOU、上海苏颉企业管理咨询合伙企业（有限合伙）共同构成单一最大股东集团，后者持有的股权份额分别为1.86%、1.71%、7.96%。也就是说，Michael Min XU与其一致行动人合计持有派格生物27.37%的股权。招股书显示，Michael Min XU是派格生物的创始人、董事长、执行董事兼总经理，在医疗保健行业拥有超过30年的工作及管理经验，创立派格生物前，曾先后任湘雅医学院眼科医生、哥伦比亚大学医学院分子识别中心及生物化学和分子生物学系研究员等，美国国籍。招股书显示，2008—2023年，派格生物共计进行了9轮融资，累计获得5030亿美元和10.47亿元人民币的资金。最后一轮融资发生于2023年6月，此轮融资派格生物共获得1.34亿元人民币，投后估值达到40亿元。行业竞争格局：核心产品所属赛道越来越拥挤糖尿病是一种慢性及代谢疾病，表现为血糖水平异常高。2018—2023年，我国T2DM患者数量从1.15亿人增加到1.25亿人，复合年增长率为1.7%，预计到2032年将增加到1.42亿人，2023—2032年的复合年增长率为1.4%。 T2DM的治疗方案以胰岛素疗法和糖尿病药物为主，其他治疗方式还包括胰高血糖素样肽-1（GLP-1）受体激动剂、噻唑烷二酮类（TZD）、口服磺脲类、二肽基肽酶-4（DPP-4）抑制剂等。派格生物的PB-119就是一种GLP-1受体激动剂。中国拥有庞大的人口基数，其中T2DM患者为全球之最，市场潜力巨大。2018—2023年，我国T2DM药物的市场规模从546亿元增长至607亿元，复合年增长率为2.1%。其中，GLP-1的市场规模从7亿元增长至87亿元，复合年增长率达到69.1%。招股书显示，2032年，我国T2DM药物的市场规模预计将达到1166亿元，2023—2032年的复合年增长率为7.5%；其中，2032年GLP-1的市场规模预计达到688亿元，2023—2032年的复合年增长率为25.9%，将成为T2DM药物中占比最高的种类。广阔的市场也吸引了大批药企的参与招股书显示，截至最后实际可行日期，已经有超过300种二甲双胍产品、超过50种胰岛素产品、超过30种SGLT-2抑制剂产品及超过40种DPP-4抑制剂产品于美国获FDA批准用于治疗T2DM，还有一种GLP-1/GIP双受体激动剂替尔泊肽获FDA及国家药监局各自批准用于治疗T2DM或肥胖症。同时，国内有超过250种二甲双胍产品、至少超过50种胰岛素产品以及超过35种SGLT-2抑制剂产品和超过40种DPP-4抑制剂产品获国家药监局批准用于治疗T2DM。另外，一旦品牌药的相关专利到期，仿制药的潜在发展也将导致市场的竞争更为激烈。而派格生物的PB-119产品上市后，能否从激烈的市场竞争中脱颖而出，目前仍未得到验证。三、财务数据：尚未实现商业化，研发开支下降未有产品商业化，公司长期亏损除了PB-119，派格生物还有5款候选产品，包括PB-718、PB-1902、PB-722、PB-2301、PB-2309等，涵盖了T2DM、肥胖症、非酒精性脂肪性肝炎（NASH）、阿片类药物引起的便秘（OIC，使用阿片类药物引起的胃肠道疾病）及先天性高胰岛素血症（一种罕见的内分泌疾病，患者持续出现低血糖症）等常见慢病及代谢疾病的市场机会。其中，PB-119是最接近商业化的产品，该产品在中国用于治疗T2DM的新药上市申请（NDA）已于2023年9月获得国家药监局的受理，派格生物在招股书中表示，预计该药物将于2025年第一季度获准在中国上市。也就是说，到目前为止，派格生物仍未有产品获得商业化。而由于药物研发需要投入大量的资金，因此，自成立以来派格生物一直处于大幅亏损状态。根据派格生物2021年8月披露的《科创板首次公开发行股票招股说明书（申报稿）》（下称“科创板招股书”），2018—2021年第一季度各期，派格生物的净亏损分别为0.93亿元、2.10亿元、1.32亿元、0.42亿元，合计亏损4.76亿元。在2022年至2024年前8个月这一统计时段（以下简称“报告期”）内，派格生物的财务状况显示，其净亏损额分别为3.06亿、2.79亿和2.02亿元，累计净亏损高达7.88亿元。进一步推算，自2018年起，派格生物的净亏损总额已至少攀升至12.64亿元。与此同时，其研发支出却呈现出截然不同的走势。据招股说明书披露，报告期内，派格生物的研发费用分别为2.80亿、2.37亿和0.76亿元。具体来看，2023年至2024年前8个月，其研发支出同比分别减少了15.55%和51.83%。派格生物在招股书中解释，这一变化与其核心产品-119从临床试验阶段迈向提交审批阶段紧密相关。深入剖析研发支出构成，报告期内，-119产品的研发费用分别为1.56亿、0.61亿和0.28亿元，2023年至2024年前8个月，同比降幅分别达到61.22%和29.06%，同样呈现出明显的下滑态势。相比之下，另一款产品-718的研发支出则呈现出强劲的增长势头，报告期内分别为0.08亿、0.25亿和0.22亿元，2023年至2024年前8个月，同比增速分别高达207.77%和97.61%，显示出持续上升的研发活力。然而，在同一时期内，派格生物旗下的其他几款候选药物（如-1902、-722、-2301及-2309）的研发投入分别达到了1.16亿、1.52亿和0.26亿元。值得注意的是，在2023至2024年的前八个月里，这些项目的研发支出同比变化率分别为30.43%和-75.55%，显示出2024年前八个月研发成本显著缩减。派格生物在招股说明书中解释，这种波动与各药物的临床试验进展紧密相关。尽管如此，公司仍承诺将持续加大研发力度，计划拓宽核心产品的应用范围，探索联合治疗策略，加速关键产品的研发进程，同时引入更多候选药物进入临床试验阶段，并深化临床前研究。管理成本攀升需指出的是，派格生物的财务亏损几乎全部源自研发与管理两大板块。尽管2024年前八个月研发支出有所下滑，但公司的净亏损却从2023年同期的1.87亿元扩大至2.02亿元，这一变化主要归因于管理成本的急剧上升。据招股书披露，报告期内，派格生物的管理费用分别为0.49亿、0.55亿和1.26亿元，2023至2024年前八个月的同比增长率分别为12.18%和234.65%。公司进一步说明，2024年前八个月管理成本的激增，主要是由于基于股份的薪酬支出增加了0.67亿元，加之专业咨询和服务费用上升了0.23亿元。深入分析可见，基于股份的薪酬支出是管理成本增长的主要推手。在报告期内，此类支出分别为0.19亿、0.28亿和0.86亿元，占管理总成本的比例依次为38.87%、50.65%和68.17%，呈现出明显的逐年递增态势。此外，随着公司规模的扩大和业务复杂性的增加，未来管理成本可能面临进一步上升的压力。这与董事及监事薪酬的增长趋势一致。招股书显示，报告期各期，派格生物计入损益的董事薪酬总额分别为2319万元、3164万元、8349万元，计入损益的监事薪酬总额分别为126万元、45万元、102万元，合计分别为2445万元、3209万元、8451万元。根据现行安排，派格生物估计截至2024年12月31日止年度应计予董事及监事的除税前薪酬总额为3235万元。在科创板招股书中，派格生物将华领医药-B（02552.HK）、泽璟制药-U（688266.SH）、前沿生物-U（688221.SH）、微芯生物（688321.SH）、特宝生物（688278.SH）、艾力斯（688578.SH）列为可比公司。 Wind数据显示，2023年，上述可比公司的管理层年度薪酬总额分别为2599.50万元、1904.53万元、1488.10万元、1463.41万元、1975.96万元、1805.21万元，均远低于派格生物。偿债能力低于可比公司招股书显示，报告期各期末，派格生物的流动比率分别为3.21倍、2.09倍、1.54倍，呈现大幅下降趋势，且截至2024年8月末已经降至低于理论安全水平（2倍）。 Wind数据显示，2022—2023年各期末，派格生物可比公司的流动比率均值分别为4.43倍、4.17倍，基本保持稳定，且远高于派格生物。从资产负债率来看，Wind数据显示，2022—2023年各期末，派格生物的资产负债率分别为30.14%、46.92%，一年上升16.78个百分点。同期末，可比公司资产负债率均值分别为38.66%、41.74%，一年仅上升3.08个百分点，并且2023年可比公司的资产负债率已经低于派格生物。可见，跟可比公司的平均水平相比，目前派格生物的流动性和偿债能力均较低。四、风险因素：关注经营持续性风险经营持续性风险招股书显示，2022—2024年8月、9月各期末，派格生物的现金及现金等价物分别为0.60亿元、0.77亿元、0.27亿元、0.10亿元，按公允价值计入损益的金融资产分别为3.34亿元、2.63亿元、1.94亿元、1.84亿元。由此计算，截至2024年8月末、9月末，派格生物的现金及现金等价物与按公允价值计入损益的金融资产（下称“现金及金融资产”）共计分别为2.21亿元、1.94亿元，即仅一个月派格生物的现金及金融资产就减少了0.27亿元。派格生物公开披露，其巨额亏损主要源于高额的研发与管理费用支出。具体而言，2023年度，该公司的研发与管理总费用高达2.92亿元，平均每月支出约0.24亿元。基于这一数据推算，自2024年10月起，派格生物截至2024年9月底所持有的1.94亿元资金，预计仅能支撑至2025年5月，即维持约8个月的运营。从财务稳健性指标——流动比率来看，至2024年8月末，该比率已下滑至1.54倍，低于行业公认的安全阈值。然而，派格生物在招股说明书中强调，综合考量其可动用的财务资源，包括现金、现金等价物、理财产品、银行可转让定期存单等，以及当前的现金消耗速率，公司具备充足的营运资金，足以覆盖至少125%的成本支出，这涵盖了从招股书公布日（2024年11月13日）起至少未来12个月的研发与管理开支。尽管如此，由于产品尚未实现商业化，派格生物至今未能获得任何销售收入，导致其经营现金流持续呈现净流出状态，缺乏自我“造血”的能力。时代投研分析指出，若派格生物无法顺利上市，同时亦难以获得大规模融资支持，其药物研发进程及商业化目标或将难以达成，进而威胁到公司的持续经营能力。当前，派格生物面临持续亏损的风险，主要因其尚无药品获得商业化销售许可，因此未从药品销售中获取任何收入。预计在候选药物获得商业化销售监管批准前，公司不会产生药品销售收入。此外，即便产品最终实现商业化，派格生物也预期在推广任何获批产品过程中将面临高额费用支出。派格生物进一步表示，公司实现盈利的能力取决于多重因素的成功，包括完成候选产品的非临床与临床研发研究、获得监管批准及上市许可、应对科技与市场发展的竞争挑战等。若无法从销售获批产品中获取收益，公司可能难以实现盈利目标。自成立以来，派格生物已遭受大额净亏损，未来可能继续产生净亏损，且盈利前景不明朗。在药物研发与销售领域，派格生物面临多重风险。作为创新药企，药物研发本身充满不确定性，包括药物开发、临床试验及监管审批等环节的风险。派格生物在招股书中坦言，公司可能面临激烈的市场竞争和快速的技术迭代，竞争对手可能开发出更先进或更有效的疗法，对公司的财务状况及候选药物商业化能力构成不利影响。此外，产品上市后，派格生物还可能面临大幅降价的风险。在申报科创板的过程中，上交所曾就派格生物的-1受体激动剂市场规模问题提出质疑，要求公司说明是否充分考虑了医保降价、市场竞争导致的降价、被纳入集中采购等因素。对此，派格生物在2022年1月17日公布的回复报告中指出，从当前医保谈判结果来看，-1类药物进入医保目录时均经历了大幅降价，且未来续约谈判中，产品价格可能进一步下调。派格生物还提到，目前-1类药物大部分刚进入医保目录，尚未被纳入带量采购范围。但长期来看，随着产品上市数量增加、市场规模扩大、医保基金费用占用上升，-1类药物未来可能被纳入带量采购，但具体实施时间、涉及省份、集采市场占比、降价幅度等因素存在不确定性。在募投项目方面，派格生物计划将募集资金用于核心产品-119的商业化及适应证拓展、主要产品-718的进一步开发、其他管线候选产品的研发、业务开发及海外业务拓展以及补充营运资金等。尽管-119产品已接近商业化阶段，但派格生物表示，在获得批准后，公司计划于2025年启动两项期临床试验，研究-119与基础胰岛素（119-303）或-2抑制剂（119-304）的联合疗法，并同时启动一项针对-119单药疗法的期临床试验（119-305）。此外，派格生物还计划将部分募资用于-718及其他候选药物的研发，这将有助于加速公司产品的研发进程及商业化步伐，进而提升其核心竞争力及盈利能力。然而，如前所述，创新药的研发充满挑战，药物成功商业化并与其他相同靶点的药物竞争以获取市场份额的能力，将取决于多种因素。这包括监管批准的时间表、药物疗效及安全性与竞品的比较、给药方案的便捷性、商业化合作伙伴的销售及分销渠道的定价策略以及市场覆盖范围等。派格生物需在这些方面不断努力，以应对激烈的市场竞争和不断变化的市场环境。值得注意的是，派格生物还在积极拓展海外市场，寻求更广阔的发展空间。公司计划通过海外业务拓展，将自主研发的创新药物推向国际市场，以提升公司的国际影响力和竞争力。这一战略举措不仅有助于公司分散市场风险，还能为公司带来新的增长点。然而，海外市场的拓展同样充满挑战，派格生物需充分了解目标市场的政策法规、市场需求及竞争态势，制定切实可行的市场进入策略，以确保海外业务的顺利推进。另外，从研发进度来看，目前派格生物大部分药物都处于临床或临床前研究阶段，这意味着这些药物距离商业化仍有很长的路要走，而且其结果也存在不确定性。

2025-11-17

·北京医学感染与传染研究

抗菌化疗杂志 80卷 7-11期、增刊2、4期

Journal of Antimicrobial Chemotherapy Volume 80, Issue 7抗菌化疗杂志 80卷 7期 https://academic.oup.com/jac/issue REVIEWS（综述） 1 The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review 抗生素预防用药在前列腺、乳腺及妇科癌症近距离治疗中的作用：叙述性综述 Konstantinos Alexakis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1753–1771, 2 To be or not to be: the non-antimicrobial properties of common antimicrobials 生存还是毁灭：常见抗菌药物的非抗菌特性 Shivakumar Narayanan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1772–1783, SYSTEMATIC REVIEWS（系统综述） 3 Antibiotic-induced Bartter-like syndrome: a systematic review 抗生素诱发的巴特综合征样表现：系统综述 Megha Priyadarshi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1784–1791, 4 Liposomal amphotericin B prophylaxis in paediatrics: a systematic review 两性霉素B脂质体预防性用药在儿科中的应用：系统综述 Emma V Thorley and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1792–1802, ORIGINAL RESEARCH（论著） 5 Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study 婴儿期呼吸道合胞病毒感染所致抗生素使用情况——一项国际前瞻性出生队列研究 Sarah F Hak and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1803–1812, 6 Plasmodium falciparum isolates: ex vivo drug response 恶性疟原虫分离株：体外药物反应 Edem Adika and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1813–1822, 7 Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia 低白蛋白血症对接受厄他培南联合疗法治疗甲氧西林敏感金黄色葡萄球菌菌血症患者的影响 Sunish Shah and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1823–1827, 8 Exploring community pharmacy professionals and general practitioners’ views on primary care communication and pathways to access antibiotics in England 探究英国社区药房专业人员和全科医生对初级保健沟通及获取抗生素途径的看法 Ming Xuan Lee and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1828–1836, 9 Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study 新冠疫情后铜绿假单胞菌菌血症抗菌药物耐药性的下降：一项纵向观察研究 Yulia Butscheid and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1837–1848, 10 Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 意大利HIV感染者（HIV-RNA不可检测）特定合并症与抗逆转录病毒药物转换概率：一项回顾性分析 Alessandro Cozzi-Lepri and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1849–1859, 11 Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia model 基于模型转化利奈唑胺和万古霉素对甲氧西林耐药金黄色葡萄球菌的药代动力学-药效学关系：从体外时间杀菌实验到小鼠肺炎模型 Diego Vera-Yunca and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1860–1868, 12 Inner-mitochondrial membrane protein PfMPV17 is linked to P. falciparum in vitro resistance to the indoloquinolizidine alkaloid alstonine 线粒体内膜蛋白PfMPV17与恶性疟原虫对吲哚醌啉生物碱阿尔斯通宁的体外耐药性相关 J R Macdonald and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1869–1877, 13 Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium 米诺环素与甲硝唑联合治疗大环内酯类耐药生殖支原体感染的疗效和耐受性 Kay Htaik and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1878–1884, 14 Early use of the novel antifungal rezafungin: a case series and literature review 新型抗真菌药物瑞扎芬净的早期使用：病例系列报道及文献综述 H C Davidson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1885–1892, 15 Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach 基于群体药代动力学-药效学模型方法确定阿莫西林在肥胖和胃旁路术后患者中的最佳剂量 Gisela Myrian de Lima Leite Dalla Rosa and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1893–1901, 16 Decreasing antimicrobial resistance in representative UK livestock species was associated with reduced total sales of antimicrobials in the last decade 过去十年，英国代表性家畜物种抗菌药物耐药性下降与抗菌药物总销量减少相关 Aliya El Nagar and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1902–1906, 17 An improved multiplex RT–quantitative PCR assay can reveal sex-specific activity of transmission-blocking drugs on ex vivo gametocytes from Plasmodium falciparum asymptomatic infections 一种改进的多重逆转录定量聚合酶链反应检测法可揭示性特异性抗疟疾传播阻断药物对恶性疟原虫无症状感染体外配子体活性的影响 Mariagrazia Ciardo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1907–1914, 18 Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients 利奈唑胺在肝移植受者中的群体药代动力学及血小板减少症风险评估 Xiaoping Shi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1915–1925, 19 Rapid susceptibility testing on urine for antimicrobial stewardship in general practice 全科实践中的尿液快速药敏试验助力抗菌药物管理 Patrick D J Sturm and Tanja Schülin Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1926–1932, 20 Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains 利奈唑胺单药治疗每12小时一次与每8小时一次，以及与达托霉素联合治疗甲氧西林耐药和糖肽中介金黄色葡萄球菌菌株所致实验性心内膜炎的疗效 María-Alexandra Cañas and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1933–1941, 21 In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains 新型作用机制抗菌药物NOSO-502对包括多重耐药菌株在内的肠杆菌科临床菌株的体外活性 Marie L G Attwood and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1942–1946, 22 Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions 中性及弱酸性条件下，丙二醇对金黄色葡萄球菌和表皮葡萄球菌的抗菌活性 Nadiia Mosiichuk and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1947–1950, 23 Molecular characteristics of chromosome-mediated colistin resistance in foodborne Salmonella isolates in China 中国食源性沙门氏菌分离株染色体介导的多粘菌素耐药性的分子特征 Zeqiang Zhan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1951–1963, 24 High azole non-wild type rates and nosocomial microsatellite typing aggregation of Wickerhamomyces anomalus in China according to a 12-year multicenter surveillance study 根据一项为期12年的多中心监测研究，中国异常威克汉姆酵母属唑类非野生型率高且医院内微卫星分型聚集 Zhengyu Luo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1964–1971, 25 Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus 抗疟药物再利用：乙胺嘧啶对加德纳菌的体外活性优于甲硝唑，且对乳酸杆菌无影响 Aliona S Rosca and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1972–1979, 26 Clinical characteristics and risk factors of tigecycline-induced acute pancreatitis in kidney transplant recipients: a retrospective study 肾移植受者替加环素诱发急性胰腺炎的临床特征及危险因素：一项回顾性研究 Lijuan Feng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1980–1987, 27 Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875 多重耐药鲍曼不动杆菌全球克隆1型参考菌株A297/RUH875的基因组特征 Jonathan Koong and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1988–1992, 28 Comparison of a modified broth microdilution Sensititre™ SLOMYCOI assay with the CLSI-recommended agar disk elution method for antimicrobial susceptibility testing of Mycobacterium haemophilum 改良肉汤微量稀释Sensititre™ SLOMYCOI检测法与CLSI推荐的琼脂稀释法对嗜血杆菌属抗菌药物敏感性检测的比较 Doris Hillemann and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1993–1996, 29 Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations 由于细菌噬菌体和抗生素在临床可达到浓度下的体外协同作用，多重耐药碳青霉烯酶产生肺炎克雷伯菌临床分离株的表型耐药性发生逆转 Paschalis Paranos and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1997–2006, 30 Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France 瑞典和法国假体关节感染表皮葡萄球菌的抗生素耐药性和群体结构 Sofie M Edslev and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2007–2015, 31 Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections 抗生素锁疗法与导管拔除术治疗中心血管导管感染的影响评估 Nischal Ranganath and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2016–2024, 32 Real-time FT-IR typing of Klebsiella pneumoniae: a flexible and rapid approach for outbreak detection and infection control 肺炎克雷伯菌实时傅里叶变换红外分型：一种灵活快速的暴发检测和感染控制方法 Ana Beatriz Gonçalves and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2025–2031, 33 Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori 抗生素压力影响幽门螺杆菌产生的细胞外囊泡的分泌和物理化学特性 Paweł Krzyżek and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2032–2043, 34 A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro 生殖支原体体外诱导产生的新型阿奇霉素耐药突变 Teck-Phui Chua and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2044–2050, RESEARCH LETTERS（研究信函） 35 Posaconazole dosing of enteral formulations in infants and young children to achieve therapeutic concentrations 婴儿和幼儿肠内制剂泊沙康唑的给药剂量以达到治疗浓度 Jeffrey Harrington and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2051–2053, 36 Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis 两性霉素B脂质体治疗慢性内脏利什曼病无效的肾移植受者中使用锑剂作为挽救疗法 Natacha Mrozek and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2053–2056, 37 Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis? 头孢唑林是否可用于治疗葡萄球菌性内源性眼内炎？ Alexandra Morin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2057–2058, LETTER TO THE EDITOR（致编辑的信） 38 Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre—a counterpoint 单用替考拉宁治疗肠球菌感染性心内膜炎：一家转诊中心的回顾性和比较研究——反驳观点 Miguel Villamarín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2059–2060, Journal of Antimicrobial Chemotherapy Volume 80, Issue 8 抗菌化疗杂志 80卷 8期 https://academic.oup.com/jac/issue Review(综述) 1 World Health Organisation’s Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: ‘challenges and opportunities’ 世界卫生组织2017年和2024年用以应对全球抗菌药物耐药性危机的细菌病原体优先名单（BPPL）：“挑战与机遇” Vazhayil Hari Krishnaprasad and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2061–2069 Original Research(论著) 2 Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5years of surveillance prior to approval for clinical use (2019–2023) 氨曲南/阿维巴坦对欧洲医疗中心肠杆菌科细菌的活性：临床批准前5年（2019-2023年）监测总结 Helio S Sader and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2070–2079 3 High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid 利奈唑胺唾液治疗药物监测可行性高，但替地唑胺可行性较低：一项健康受试者单剂量研究和一项接受利奈唑胺患者单中心前瞻性探索性研究 Hitoshi Kawasuji and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2080–2091 4 Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium 缩小版中空纤维感染模型的建立与验证及万古霉素对粪肠球菌的药代动力学/药效学分析 Yukitaka Hayashi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2092–2099 5 Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial 为期4个月的氯法齐明方案治疗敏感型肺结核：一项随机临床试验 Nusrat Shafiq and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2100–2108 6 An ex vivo model to determine transmembrane clearance of antimicrobials during continuous renal replacement therapy 用于确定连续性肾脏替代治疗期间抗菌药物跨膜清除率的体外模型 Cole McGrath and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2109–2116 7 Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa 黏液型铜绿假单胞菌纸片扩散法的优化与改进 Aixin Wang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2117–2125 8 HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022 乌干达接受基于多替拉韦抗逆转录病毒方案的HIV感染者中HIV-1耐药性情况：2022年一项基于国家实验室使用剩余病毒载量样本的调查 Christine Watera and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2126–2134 9 Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women 与固定剂量相比，基于体重给药的CAP256V2LS（一种用于女性HIV预防的广谱中和抗体）群体药代动力学研究 Sharana Mahomed and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2135–2144 10 Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study 接受整合酶抑制剂治疗的HIV感染者肠道微生物群与体重增加情况：一项为期五年的纵向研究 Javier García-Abellán and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2145–2157 11 Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model 慢性戊型肝炎病毒感染移植受者利巴韦林给药方案的开发：一项群体药代动力学和药效学模型研究 Midas B Mulder and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2158–2168 12 Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 长效卡博特韦/利匹韦林在病毒受抑制的HIV感染者中的治疗中断有效性和预测因素：来自Icona队列的现实数据 Roberta Gagliardini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2169–2178 13 Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial 病毒受抑制的HIV感染者中，5天用药2天停药（FOTO）方案与每日比克替拉韦/恩曲他滨/丙酚替诺福韦方案的对比：一项初步随机临床试验 Hsin-Yun Sun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2179–2186 14 Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia 青霉素敏感金黄色葡萄球菌菌血症的纸片扩散试验可靠性和分子流行病学研究 Pernilla Kihlberg and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2187–2193 15 Outcomes of ceftriaxone 2g versus 1g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study 住院肺炎患者每日头孢曲松2克与1克疗效对比：一项全国性回顾性队列研究 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2194–2202 16 Oleanolic acid derivative bardoxolone combats multidrug-resistant Staphylococcus aureus by destroying cell membrane and pyruvate metabolism pathway 齐墩果酸衍生物巴多昔隆通过破坏细胞膜和丙酮酸代谢途径对抗多重耐药金黄色葡萄球菌 Yun-Dan Zheng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2203–2213 17 Evaluation of amoxicillin and benzylpenicillin therapy in early-onset neonatal sepsis: a pharmacometric external validation and simulation study 阿莫西林和苄青霉素治疗早期新生儿败血症的评估：一项药效计量学外部验证和模拟研究 Tom C Zwart and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2214–2225 18 48Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial HIV感染者换用多替拉韦加拉米夫定治疗48周身体成分变化：DOLAM随机临床试验的计划子分析 Elisa de Lazzari and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2226–2233 19 The impact of inter-infection time on antimicrobial resistance profiles in women with multiple urinary tract infections over time 多次尿路感染女性患者感染间隔时间对抗菌药物耐药性特征的影响 Trenton Honda and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2234–2240 20 Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales 一种检测产DHA肠杆菌科细菌的新型快速免疫层析法的开发与评估 Christian Moguet and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2241–2246 21 Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes 粪肠球菌菌血症：一项关注临床和微生物学结局风险因素的多中心观察性研究 Matteo Rinaldi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2247–2256 22 Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus 靛红咔唑类化合物作为宿主导向疗法对抗甲氧西林耐药金黄色葡萄球菌细胞内感染 Robin H G A van den Biggelaar and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2257–2268 23 Clinical validation of antimicrobial dosing regimens for continuous renal replacement therapy based on an ex vivo dosing algorithm 基于体外给药算法的连续性肾脏替代治疗抗菌药物给药方案的临床验证 Christina Koenig and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2269–2279 24 Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy 意大利牛犊艰难梭菌分离株中携带cfr(B)和cfr(C)利奈唑胺耐药基因的新型整合性和接合性元件 Andrea Brenciani and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2280–2284 25 Characterization of Carbapenemase-producing Enterobacterales isolated from patients returning from Sub-Saharan Africa, France, 2015–2022 2015-2022年从撒哈拉以南非洲返回的法国患者中分离出的产碳青霉烯酶肠杆菌科细菌的特征 Corentin Poignon and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2285–2294 26 Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections 具有强生物膜形成能力的青霉素敏感ST398型对骨关节感染构成重大威胁 Ye Jin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2295–2304 27 Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB 贝达喹啉、德拉马尼和莫西沙星与不同剂量苏特唑利或德帕唑利联合用药治疗药物敏感型肺结核的心脏安全性 Simon E Koele and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2305–2313 28 Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study 头孢托唑坦/他唑巴坦与美罗培南治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染的对比：一项单中心回顾性现实研究 Dimitrios Basoulis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2314–2322 Research Letters(研究信件) 29 Dalbavancin as chronic suppressive therapy in a patient undergoing monthly apheresis: a case report with therapeutic drug monitoring 达巴万星作为每月进行血浆置换术患者的长期抑制治疗：一项带治疗药物监测的病例报告 Carlo Pallotto and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2323–2324 30 A novel methicillin-resistant Staphylococcus aureus lineage (ST4174) with an uncharacterized SCCmec variant identified in Korean pigs 韩国猪体内发现的一种带有未表征SCCmec变体的新型甲氧西林耐药金黄色葡萄球菌谱系（ST4174） Hyeonwoo Cho and Kun Taek Park Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2325–2326 31 Time fixes everything, but not always: 10years of persistent PI mutations in the absence of pharmacological pressure—a case report 时间能治愈一切，但并非总是如此：无药物压力下持续10年的蛋白酶抑制剂突变——一例病例报告 Layla Pagnucco and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2327–2330 32 Carbapenem resistance in Escherichia marmotae: characterization of IncL plasmids carrying blaOXA-48 土拨鼠埃希菌的碳青霉烯耐药性：携带blaOXA-48的IncL质粒特征 Astrid Rasmussen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2330–2331 Letters to the Editor(致编辑的信) 33 Comment on: Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital 述评：产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究 Jianjun Li and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2332 34 Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a Tertiary University Hospital—right to reply—author’s response 产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究——作者回复 Gulhadiye Avcu Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2332–2333 Corrections(更正) 35 Correction to: Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD) 更正：索非布韦作为黄热病相关内脏热带病（YEL-AVD）暴露后预防用药 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2334 36 Correction to: Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs 更正：维也纳犬体内发现与人相关的大流行性产超广谱β-内酰胺酶大肠杆菌ST38、ST131和ST141谱系 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2335 37 Correction to: GP or ChatGPT? Ability of large language models (LLMs) to support general practitioners when prescribing antibiotics 更正：全科医生还是ChatGPT？大型语言模型（LLM）在全科医生开具抗生素处方时的辅助能力 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2336 Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2 抗菌化疗杂志 80卷增刊2期 https://academic.oup.com/jac/issue SUPPLEMENT (补充) CANWARD 2007-23 加拿大抗感染耐药监测项目（CANWARD）2007-2023年数据/报告 Foreword(前言) 1 The CANWARD studies: Canadian Antimicrobial Resistance Alliance (CARA) Canadian Hospital Ward Antibiotic Resistance Surveillance collection 加拿大抗感染耐药监测项目研究：加拿大抗微生物耐药联盟（CARA）加拿大医院病房耐药性监测数据集 James C Hurley and Jean-Yves Madec Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Page ii1 Supplement Papers(补充论文) 2 Seventeen years of the CANWARD study (2007–23) 加拿大抗感染耐药监测项目研究17年（2007-2023年） George G Zhanel and Heather J Adam Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii2–ii4 3 Gram-positive pathogens from Canadian hospitals: 17years of results from the CANWARD study (2007–23) 来自加拿大医院的革兰氏阳性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023） George G Zhanel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii5–ii14 4 Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23) 来自加拿大医院的革兰氏阴性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023） George G Zhanel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii15–ii26 5 Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23) 加拿大医院耐甲氧西林金黄色葡萄球菌的特征：加拿大抗感染耐药监测项目研究的17年（2007-2023） Anissa Brahami and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii27–ii34 6 Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007–23) 加拿大抗感染耐药监测项目研究中加拿大医院血液培养和呼吸道标本中肺炎链球菌抗微生物药物耐药性和血清型的比较（2007-23） Heather J Adam and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii35–ii44 7 Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23 加拿大医院中产生ESBL的大肠杆菌和肺炎克雷伯菌的比率增加：加拿大抗感染耐药监测项目研究17年，2007-2023 Philippe Lagacé-Wiens and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii45–ii53 8 Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23) 加拿大医院耐厄他培宁肠杆菌的特征：17年的加拿大抗感染耐药监测项目研究（2007-23） Laura F Mataseje and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii54–ii61 9 Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6years of the CANWARD study (2018–23) 加拿大医院耐碳青霉烯假单胞菌的特征：6年的加拿大抗感染耐药监测项目研究（2018-23） Melissa McCracken and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii62–ii71 10 Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007–23) 加拿大患者血液中病原菌的分布和药敏特征：来自加拿大抗感染耐药监测项目研究（2007-23）的结果 Andrew Walkty and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii72–ii82 Journal of Antimicrobial Chemotherapy Volume 80, Issue 9抗菌化疗杂志 80卷 9期 https://academic.oup.com/jac/issue VIEWPOINT（观点） 1 Classifying patients with invasive fungal disease: towards a unified case definition? 侵袭性真菌病患者分类：能否达成统一的病例定义？ Mehmet Ergün and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2337–2343, SYSTEMATIC REVIEW（系统综述） 2 Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis 早期转换为口服抗生素治疗革兰氏阳性菌血流感染的疗效和安全性：一项系统综述和荟萃分析 ZhaoYi Tan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2344–2360, ORIGINAL RESEARCH（论著） 3 Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium 屎肠球菌中那拉霉素、盐霉素、拉沙洛西钠和莫能菌素流行病学临界值的测定 Maria Laura Ferrando and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2361–2368, 4 Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era 四类耐药HIV感染者体内CXCR4嗜性病毒的持续存在及其在现代抗逆转录病毒治疗时代的临床影响 Rebecka Papaioannu Borjesson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2369–2374, 5 Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks 随机试验中96周内使用多替拉韦或对照抗逆转录病毒疗法对高血压和血压变化的影响 Parul Patel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2375–2383, 6 Comparative analysis of lipid profile changes in treatment-naïve people living with HIV on INSTI-based single-tablet regimens, BIC/FTC/TAF and DTG/3TC: real-world evidence from South Korea 基于整合酶抑制剂的单片复方制剂BIC/FTC/TAF和DTG/3TC在韩国初治HIV感染者中血脂谱变化的比较分析：来自现实世界的证据 So Yun Lim and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2384–2390, 7 A novel multilocus sequence typing scheme for Morganella spp.: population structure and introduction of quantitative metric for standardization of MLST scheme 摩根氏菌属的一种新型多位点序列分型方案：群体结构及引入用于标准化多位点序列分型方案的定量度量标准 Aymeric Jacquemin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2391–2398, 8 Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya 2022年肯尼亚霍乱疫情中产超广谱β-内酰胺酶的多重耐药霍乱弧菌O1株的基因组特征 Diana Imoli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2399–2407, 9 Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection 经验性抗万古霉素耐药肠球菌治疗对万古霉素耐药肠球菌血流感染患者生存率的影响 Tao-Hung Ou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2408–2416, 10 Safety of topical tobramycin powder during operative treatment of fractures 骨折手术中使用局部妥布霉素粉末的安全性 Gregory M Schrank and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2417–2420, 11 Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS 复方磺胺甲恶唑与噬血细胞性淋巴组织细胞增多症（HLH）的风险：基于FAERS数据库个案安全报告的文献综述和比例失衡分析 Rinko Lau and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2421–2427, 12 Highly drug-resistant Vibrio cholerae harbouring blaPER-7 isolated from travellers returning to England 从返回英国的旅行者中分离出携带blaPER-7基因的高度耐药霍乱弧菌 Satheesh Nair and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2428–2432, 13 Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics 克服幽门螺杆菌的抗菌药物耐药性：附带敏感性和生物膜动态的作用 Siddharth Singh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2433–2441, 14 Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae 四种未接触过但对头孢地尔耐药的产NDM肺炎克雷伯菌所致血流感染的临床和微生物学分析 Maria Mazzitelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2442–2446, 15 Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo DHA27与庆大霉素联合对耐甲氧西林金黄色葡萄球菌的体内外协同作用 Xuemin Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2447–2458, 16 A multicentre study for determination of epidemiological cut-off values for Candida auris with EUCAST broth microdilution reference methodology 采用EUCAST肉汤微量稀释参考方法进行耳念珠菌流行病学临界值的多中心测定研究 Joseph Meletiadis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2459–2465, 17 Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study 万古霉素耐药对屎肠球菌血流感染归因死亡率的影响：一项大型多中心回顾性研究的倾向评分分析 M Del Monte and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2466–2473, 18 Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient 异基因造血干细胞移植受者中CMV和EBV双重再激活的动态变化及耐药性的出现 Martyna Pociupany and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2474–2483, 19 Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy 意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况 Angelo Roberto Raccagni and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2484–2486, 20 Comparing the mortality of patients with sepsis using empirical piperacillin/tazobactam and cefepime: analysis of the MIMIC-IV database 使用经验性哌拉西林/他唑巴坦和头孢吡肟的脓毒症患者死亡率比较：基于MIMIC-IV数据库的分析 Yongseop Lee and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2487–2495, 21 Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024 2024年中国河南省HIV-1感染者传播耐药情况 Jinjin Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2496–2502, 22 Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance A类碳青霉烯酶基因blaFRI拷贝数的波动似乎赋予了高水平碳青霉烯耐药性 Makiko Noda and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2503–2512, 23 In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization 头孢比罗联合氨苄西林对引起感染性心内膜炎的粪肠球菌的体外活性：表型和基因型特征 Clara Moretó-Castellsaguéand others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2513–2523, 24 Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates 达巴万星与β-内酰胺类药物对心内膜炎相关粪肠球菌临床分离株的矛盾相互作用 David Luque Paz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2524–2529, 25 Comparative evaluation of broth microdilution and gradient diffusion methods in Burkholderia cepacia complex susceptibility testing: implications of transitioning to ECV-based interpretation 伯克霍尔德菌复合群药敏试验中肉汤微量稀释法和梯度扩散法的比较评估：向基于ECV解释转变的影响 Wenjie Cui and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2530–2540, 26 Strengthening antimicrobial resistance diagnostics in National Reference Laboratories across One Health in South and Southeast Asia: impact of external quality assessment and targeted follow-up 加强南亚和东南亚“同一健康”国家参考实验室的抗菌药物耐药性诊断能力：外部质量评估和针对性随访的影响 Freshwork Ayalew Abegaz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2541–2549, RESEARCH LETTERS（研究快信） 27 TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient 治疗药物监测指导下的美罗培南/瓦博巴坦疗法成功治疗儿童肝移植受者中产KPC且对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌引起的腹腔和血流感染 Giovanni Mulé and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2550–2552, 28 Novel tmexC7D2-toprJ5 gene cluster and transposon Tn7759 carrying blaVIM-2 and blaOXA-10 genes in a carbapenem-resistant Pseudomonas putida from urban sewage 城市污水中碳青霉烯耐药恶臭假单胞菌中携带blaVIM-2和blaOXA-10基因的新型tmexC7D2-toprJ5基因簇和转座子Tn7759 Xinyuan Qiu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2552–2555, 29 Characterization of multiresistance gene optrA in Bacillus subtillis from China 中国枯草芽孢杆菌中多重耐药基因optrA的特征分析 Yongliang Che and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2555–2557, 30 Genomic characterization of a multidrug-resistant Mammaliicoccus sciuri strain isolated from urine of a patient from China 从中国患者尿液中分离出的一株多重耐药马氏鼠球菌的基因组特征 Fuqiang Ye and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2558–2560, LETTERS TO THE EDITOR（致编辑的信） 31 Comment on: Isavuconazole therapeutic drug monitoring and association with adverse events 关于“艾沙康唑治疗药物监测及其与不良反应的关联”的评论 Mi Zhou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2561–2562, 32 Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalised patients with pneumonia: a nationwide retrospective cohort study 关于“住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究”的评论 Satoru Mitsuboshi Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Page 2563, 33 Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—authors’ response 住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究——作者回复 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2563–2564, Journal of Antimicrobial Chemotherapy Volume 80, Issue 10抗菌化疗杂志 80卷 10期 https://academic.oup.com/jac/issue REVIEWS（综述） 1 Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead 长效卡博特韦和利匹韦林治疗HIV感染者的现状与未来挑战 Luis Buzón-Martín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2565–2586, 2 Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal 系统综述与《抗菌化疗杂志》：过去、现在与未来——系统再评估 James C Hurley Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2587–2596, SYSTEMATIC REVIEWS（系统综述） 3 Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology 研究肺结核治疗的肺内药代动力学：方法学的系统综述 Isabella van der Feltz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2597–2608, 4 Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis 全球人类中耐呋喃妥因的尿路致病性大肠埃希菌（UPEC）流行率：系统综述与荟萃分析 Christopher Larkin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2609–2621, ORIGINAL RESEARCH（研究论著） 5 Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium? 氨苄青霉素联合头孢菌素是否为氨苄青霉素敏感的粪肠球菌的治疗选择？ Paula Bierge and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2622–2629, 6 Therapeutic efficacy monitoring of pyronaridine–artesunate (Pyramax®) in treating uncomplicated Plasmodium falciparum malaria in Gia Lai province, Vietnam from 2022 to 2023 2022-2023年越南嘉莱省青蒿琥酯-吡咯尼抗（Pyramax®）用于无并发症恶性疟原虫疟疾的治疗效果监测 Nguyen Van Thanh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2630–2634, 7 Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia 哌拉西林/他唑巴坦负荷剂量用于革兰氏阴性菌血症患者延长输注给药的有效性 Savan Patel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2635–2643, 8 Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia 连续输注大剂量头孢比罗在社区获得性肺炎危重患者中的肺内浓度 Claire Roger and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2644–2653, 9 Cefixime versus benzathine penicillin G for the treatment of early syphilis—a randomized, controlled open label trial 头孢克肟与苄星青霉素G治疗早期梅毒的随机对照开放标签试验 Tamara Klementová and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2654–2658, 10 Trends in antifungal use among hospitalized patients in the USA, 2018–23 2018-2023年美国住院患者抗真菌药物使用趋势 Dallas J Smith and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2659–2664, 11 Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study BCID2和快速AST VITEK® REVEALTM对革兰氏阴性菌血流感染危重患者抗生素优化的临床影响：一项准实验性前后干预研究 Louis Oudiane and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2665–2675, 12 In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium 甲砜霉素对药物敏感和耐药生殖支原体菌株的体外活性 Sofie Skovmand and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2676–2681, 13 A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model 基于群体药代动力学模型的左氧氟沙星剂量方案先验优化 Emmanuel Enard and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2682–2692, 14 Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis 危重患者头孢他啶-阿维巴坦的模型知情个体化给药：群体药代动力学研究和参数时间事件分析 Tingting Wu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2693–2704, 15 Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria 开发血培养阳性时间作为监测针对多重耐药革兰氏阴性菌抗生素治疗的药效动力学指标 Irene Zaghi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2705–2713, 16 In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model 头孢布坦-莱达博巴坦口服联合用药对产丝氨酸-β-内酰胺酶肠杆菌科细菌的体内活性评估：在肾盂肾炎和膀胱炎小鼠模型中的评估 Christina Koenig and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2714–2718, 17 Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial 健康受试者静脉注射后口服奥马环素的粪便药代动力学、微生物组和胆汁酸变化：一项1期临床试验 Jinhee Jo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2719–2726, 18 Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application 抗逆转录病毒治疗依从性干血斑检测法的实验室间比对：对临床应用的启示 Nathan Engel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2727–2731, 19 A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study 意大利北部长效注射用卡博特韦和利匹韦林有效性、持久性和安全性的现实中多中心前瞻性队列研究：LONGITUDE研究 Maria Mazzitelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2732–2741, 20 Assessment of the risk of developing cefepime-induced abnormal liver enzyme levels using the albumin–bilirubin score and fibrosis-4 index: a single-centre retrospective case–control study 使用白蛋白-胆红素评分和纤维化-4指数评估头孢吡肟诱导的肝酶水平异常发生风险：一项单中心回顾性病例对照研究 Hiroki Katsu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2742–2751, 21 Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial BALANCE临床试验中血流感染患者的临床病程 Sean W X Ong and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2752–2758, 22 Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study 神经重症患者中多黏菌素治疗碳青霉烯类耐药革兰氏阴性菌肺炎的结果比较：一项回顾性队列研究 Qian Zeng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2759–2772, 23 Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates 肉鸡和人类临床分离的粪肠球菌中NarAB的不同群体结构和基因组背景 Jayanth Balakuntla and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2773–2781, 24 Population pharmacokinetics of bictegravir in real-world people with HIV 现实中HIV感染者比克替拉韦的群体药代动力学 Pierre Ekobena and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2782–2789, 25 Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index 活动性肺结核整个治疗期间利福平浓度：性别和体重指数的影响 Teres Samuelsson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2790–2798, 26 Performance of disc diffusion and gradient strip test on different Mueller–Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa 在碳青霉烯类耐药铜绿假单胞菌中对头孢地尔敏感性测试使用不同穆勒-欣顿琼脂培养基平板和ComASP®及Bruker UMIC®头孢地尔微量稀释板的纸片扩散法和梯度条带测试的性能 Stefano Mancini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2799–2806, 27 Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model 在离体人类绒毛叶模型中治疗COVID-19的药物莫努匹拉韦、法维拉韦和奈玛特韦/利托那韦的胎盘转移 Solene Labaye and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2807–2813, 28 Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms 针对具有多种耐药机制的高度耐药鲍曼不动杆菌患者分离株的含头孢地尔抗生素联合用药的协同作用 Justin Halim and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2814–2824, 29 Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France 2015-2022年药物减量抗逆转录病毒策略的采用情况及对成本的影响：来自法国巴黎一家HIV诊所的经验 L Sagaon-Teyssier and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2825–2833, 30 Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin 对达拉氟沙星敏感的侵袭性临床肺炎链球菌分离株中氟喹诺酮耐药性的分子特征 Emilia Cercenado and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2834–2843, 31 Genomic structure of class 1 and 2 integrons in non-typhoidal Salmonella isolated from food animals and related meat products in the USA 美国食品动物及其相关肉类产品中分离的非伤寒沙门氏菌1类和2类整合子的基因组结构 Chih-Hao Hsu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2844–2853, 32 Characterization of blaOXA-542-mediated carbapenem resistance in Acinetobacter baumannii 鲍曼不动杆菌中blaOXA-542介导的碳青霉烯类耐药性的特征 Jingchen Hao and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2854–2861, 33 Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones 各种诺卡氏菌属临床分离株对碳青霉烯类和氟喹诺酮类的表型和基因型特征 Jing Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2862–2872, RESEARCH LETTERS（研究快报） 34 Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option? 奥利他万星治疗粪肠球菌复发性心内膜炎患者：一种新的治疗选择？ Giulia Turicchi and Marco Bongiovanni Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2873–2874, 35 The catA1 chloramphenicol resistance gene originated in Atlantibacter hermannii catA1氯霉素耐药基因起源于大西洋菌属赫尔曼尼菌 Robert A Moran and Ruth M Hall Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2874–2876, 36 Horizontal transmission of a multidrug-resistant IncM1 plasmid harbouring blaOXA-48 and blaCTX-M-14b among patient microbiotas 携带blaOXA-48和blaCTX-M-14b的多重耐药IncM1质粒在患者微生物群中的水平传播 Roberto Sierra and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2876–2879, 37 Antimicrobial activity of temocillin on ceftriaxone-resistant and ceftriaxone-susceptible isolates of Neisseria gonorrhoeae 替莫西林对头孢曲松耐药和头孢曲松敏感淋病奈瑟菌分离株的抗菌活性 Julie Brousseau and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2879–2881, LETTERS TO THE EDITOR（致编辑的信） 38 Comment on: Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus 述评：抗生素联合用药对临床分离的鸡肠球菌和粪肠球菌的杀菌活性 Karl Oldberg and Magnus Rasmussen Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2882–2883, 39 Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study 述评：住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究 Giancarlo Ceccarelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2884–2885, 40 Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—right to reply—authors’ response 住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究——作者回应权——作者回复 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2885–2886, Journal of Antimicrobial Chemotherapy Volume 80, Issue Supplement_4抗菌化疗杂志 80卷增刊4期 https://academic.oup.com/jac/issue/80/Supplement_4 SUPPLEMENT（补充） Two Decades of BSAC Resistance Surveillance 英国抗菌化疗学会二十年耐药性监测 FOREWORD（前言） 1 Two Decades of BSAC Resistance Surveillance 英国抗菌化疗学会二十年耐药性监测 James C Hurley and Alan P Johnson Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Page iv1, SUPPLEMENT PAPERS（补充论文） 2 Two decades of resistance surveillance by the British Society for Antimicrobial Chemotherapy: design, development, delivery, deficiencies and future directions 英国抗菌化疗学会二十年耐药性监测：设计、发展、实施、不足与未来方向 Alasdair P MacGowan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv2–iv6, 3 The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations 英国抗菌化疗学会耐药性监测项目：方法与局限性 Michael Allen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv7–iv21, 4 Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019 英国和爱尔兰地区革兰氏阳性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv22–iv35, 5 Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019 英国和爱尔兰地区革兰氏阴性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv36–iv48, 6 Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019 英国和爱尔兰地区医院获得性下呼吸道感染病原体的抗菌药物耐药性趋势（2008/2009 - 2018/2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv49–iv59, 7 Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019 英国和爱尔兰地区社区获得性下呼吸道感染病原体的抗菌药物耐药性趋势（1999/2000 - 2018/2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv60–iv71, 8 Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999–2019) 英国和爱尔兰地区肺炎链球菌血清型及耐药性趋势（1999 - 2019年） Carolyne Horner and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv72–iv86, 9 Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project—legacy and future 英国抗菌化疗学会耐药性监测项目的应用与益处——成果与未来 Benjamin J Parcell and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv87–iv95, Journal of Antimicrobial Chemotherapy Volume 80, Issue 11抗菌化疗杂志 80卷 11期 https://academic.oup.com/jac/issue VIEWPOINTS（观点） 1 Modification of antimicrobial susceptibility testing methods 抗菌药物敏感性检测方法的修改 Ian Morrissey and Jean B Patel Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2887–2888, 2 Viewpoint: global antimicrobial stewardship accreditation is needed: the experience in Kentucky, USA 观点：需要建立全球抗菌药物管理认证体系：美国肯塔基州的经验 Ashley M Wilde and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2889–2891, REVIEWS（综述） 3 Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules 噬菌体揭示抗菌药物耐药性的生物学脉络：从起源与传播到替代治疗模式 Cleo Anastassopoulou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2892–2901, 4 Molecular drivers of fusion plasmid: mechanistic insights and evolutionary implications 融合质粒的分子驱动因素：机制见解与进化意义 Ziyi Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2902–2911, ORIGINAL RESEARCH（研究论著） 5 Emergence of livestock-associated MRSA clonal complex 398 in Thailand’s swine industry 泰国养猪业中出现与牲畜相关的MRSA克隆复合体398 Pawarut Narongpun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2912–2917, 6 Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series 长期使用替达拉韦抑制治疗期间出现周围神经病变：系列病例报告 Tomaso Beringheli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2918–2922, 7 Low bacterial metabolism as a central mechanism of antimicrobial resistance and potential therapeutic target of staphylococcal biofilms in ventricular assist device driveline infections 细菌低代谢作为抗菌药物耐药性的核心机制及心室辅助装置驱动线感染中葡萄球菌生物膜的潜在治疗靶点 Yao Sun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2923–2933, 8 The pivotal role of acnA in linking carbon metabolism to virulence and antimicrobial resistance in methicillin-resistant Staphylococcus aureus acnA在连接碳代谢与耐甲氧西林金黄色葡萄球菌的毒力和抗菌药物耐药性中的关键作用 Jiahui Li and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2934–2944, 9 Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study 接受以依非韦伦为基础的抗逆转录病毒治疗的HIV-结核病共感染患者中利福平和异烟肼的药代动力学：ANRS12292-RIFAVIRENZ子研究 Thibaut Gelé and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2945–2953, 10 Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare 胞内分枝杆菌中与氯法齐明耐药相关的新型突变 Xiuzhi Jiang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2954–2957, 11 Physiologically informed in vitro framework reveals context-dependent combinatory activity of niclosamide–colistin against Gram-negative bacteria 基于生理信息的体外框架揭示了针对革兰氏阴性菌的硝基咪唑-多粘菌素组合的情境依赖性活性 Mariana Romero-Gonzalez and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2958–2969, 12 In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin 体外进化揭示生殖支原体对莫西沙星的耐药机制 Teck-Phui Chua and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2970–2977, 13 The toxin–antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening 毒素-抗毒素系统SavRS通过介导细胞壁增厚促进万古霉素中间型金黄色葡萄球菌对万古霉素的耐药性 Weifeng Xu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2978–2988, 14 Molecular insights into carbapenemase-producing Enterobacterales from Senegal 塞内加尔产碳青霉烯酶肠杆菌目细菌的分子特征 Ousmane Sow and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2989–3000, 15 Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients 老年患者中利奈唑胺及其代谢产物PNU-142300的群体药代动力学模型 Xianglong Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3001–3010, 16 In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus: a multicenter study in China 在中国开展的一项多中心研究中，康替唑胺及其他对照药物对临床分离的金黄色葡萄球菌和肠球菌的体外活性 Rongqi Lu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3011–3020, 17 Co-existence of the oxazolidinone resistance genes cfr and optrA on a novel multiresistance plasmid from a methicillin-resistant Macrococcoides bohemicum strain 从一株耐甲氧西林的马科考代菌属波希米亚菌株中发现的携带恶唑烷酮耐药基因cfr和optrA的新型多重耐药质粒 Yao Zhu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3021–3025, 18 Multidrug resistance and recurrence in urinary bacteraemia among cancer patients 癌症患者中尿路菌血症的多药耐药性和复发情况 Ignacio Grafia and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3026–3033, 19 Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection 在严重的体内感染期间，ST11型碳青霉烯耐药且高毒力的肺炎克雷伯菌中blaKPC变体的快速替代导致头孢他啶/阿维巴坦耐药 Ping Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3034–3042, 20 Potential human health risk of carbapenem-non-susceptible Pseudomonas aeruginosa from companion animals 伴侣动物中碳青霉烯类不敏感铜绿假单胞菌对人类健康的潜在风险 Jirachaya Toyting-Hiraishi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3043–3056, 21 Assessment of an LC coupled with tandem MS (LC-MS/MS) tool in the detection of antimicrobial resistance mechanisms in Enterobacterales 液相色谱-串联质谱（LC-MS/MS）工具在检测肠杆菌目细菌抗菌药物耐药机制中的应用评估 Anna Witkowska and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3057–3064, 22 Multidrug efflux pumps and innate azole resistance of Mucor lusitanicus 毛霉属葡萄牙菌的多药外排泵及其固有唑类耐药性 Stephanie Toepfer and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3065–3078, 23 Ivermectin dosing for children under 2 years 2岁以下儿童的伊维菌素剂量 Wenyu Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3079–3081, 24 Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 一线拉米夫定/多替拉韦抗逆转录病毒疗法在HIV感染者中的有效性：来自ICONA基金会队列的现实数据 Alessandra Vergori and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3082–3091, 25 Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic 城市学术型HIV诊所中长效注射用卡博特韦-利匹韦林启动的资格及关联因素 Geoffroy Liegeon and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3092–3100, 26 Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry 在接受抑制性抗逆转录病毒治疗的高度治疗经验丰富和多药耐药个体中，HIV-1 DNA耐药演变的评估：来自PRESTIGIO登记处的纵向研究 D Armenia and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3101–3106, 27 Sequential antibiotic exposure restores antibiotic susceptibility 序贯抗生素暴露恢复抗生素敏感性 Farhan R Chowdhury and Brandon L Findlay Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3107–3117, 28 Dermatological adverse effects of doxycycline as post-exposure prophylaxis for sexually transmitted infections among men who have sex with men: real-world findings from a multicentre study 在男男性行为者中，使用多西环素作为性传播感染暴露后预防的皮肤科不良反应：一项多中心研究的现实发现 Ling-Ya Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3118–3122, 29 Phenotype–genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt 埃及导管相关尿路感染中分离的革兰氏阴性尿路病原菌抗菌药物耐药性表型-基因型不一致性 Mohamed Eladawy and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3123–3132, 30 How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy? 在抗逆转录病毒治疗管理中，应如何考虑APOBEC3诱导的耐药突变？ Marie Gilbert and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3133–3138, 31 In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species 奥洛芬和抗真菌药物组合对曲霉菌和念珠菌属的体外评价 Corinne Pinder and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3139–3149, 32 Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis 在侵袭性肺曲霉病小鼠模型中，泊沙康唑与奥洛芬之间的拮抗作用 Christopher A Darlow and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3150–3159, 33 High level of archived and circulating HIV-1 drug resistance mutations in adolescents with a detectable viremia in Cameroon 喀麦隆可检测到病毒载量的青少年中HIV-1药物耐药突变的存档和循环水平较高 Armando B D Djiyou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3160–3164, RESEARCH LETTERS（研究快讯） 34 SCY-247, a novel second-generation triterpenoid antifungal, demonstrates high in vitro activity against genetically diverse Candida auris isolates, including FKS1 mutants 新型第二代三萜类抗真菌药物SCY-247对包括FKS1突变体在内的多种基因型耳道假丝酵母菌显示出高体外活性 Bram Spruijtenburg and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3165–3166, 35 Drug–drug interactions between tirzepatide and antiretrovirals: time to reassess and reassure? 替西帕肽与抗逆转录病毒药物之间的药物-药物相互作用：是时候重新评估和安心了吗？ Andrea Poloni and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3167–3168, 36 Does the use of topical azoles have an impact on antifungal resistance? 局部使用唑类药物对抗真菌耐药性有影响吗？ Jean-Yves Maillard Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3168–3186, 37 Leakage of cabotegravir and rilpivirine in HIV patients receiving long-acting injectable antiretroviral therapy 接受长效注射用抗逆转录病毒治疗的HIV患者中卡博特韦和利匹韦林的泄漏情况 Samir Benkouiten and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3187–3188, CORRECTION（更正） 38 Correction to: Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae 更正：对四种产NDM且之前未接触过头孢地洛的耐药肺炎克雷伯菌引起的血流感染的临床和微生物学分析 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Page 3189,

100 项与磷酸特地唑胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09686	磷酸特地唑胺	J01XX11	DB09042

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
葡萄球菌感染	日本	Merck Sharp & Dohme Corp.	2018-03-23
复杂的皮肤和软组织感染	日本	Merck GmbH	2018-03-12
细菌感染	韩国	Dong-A ST Co., Ltd.	2015-04-17
皮肤和皮肤结构感染	美国	Cubist Pharmaceuticals LLC	2014-06-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
呼吸机相关性肺炎	临床3期	美国	Trius Therapeutics, Inc.	2014-06-19
呼吸机相关性肺炎	临床3期	美国	拜耳医药保健有限公司	2014-06-19
呼吸机相关性肺炎	临床3期	澳大利亚	拜耳医药保健有限公司	2014-06-19
呼吸机相关性肺炎	临床3期	澳大利亚	Trius Therapeutics, Inc.	2014-06-19
呼吸机相关性肺炎	临床3期	奥地利	Trius Therapeutics, Inc.	2014-06-19
呼吸机相关性肺炎	临床3期	奥地利	拜耳医药保健有限公司	2014-06-19
呼吸机相关性肺炎	临床3期	比利时	拜耳医药保健有限公司	2014-06-19
呼吸机相关性肺炎	临床3期	比利时	Trius Therapeutics, Inc.	2014-06-19
呼吸机相关性肺炎	临床3期	波斯尼亚和黑塞哥维那	Trius Therapeutics, Inc.	2014-06-19
呼吸机相关性肺炎	临床3期	波斯尼亚和黑塞哥维那	拜耳医药保健有限公司	2014-06-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03217565 (MK-1986-014, CTgov)	临床1期	革兰氏阳性细菌感染	47	IV Tedizolid Phosphate (Part A Group 2 Cohort 1: Single Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days)	選選觸醖鏇蓋遞繭網鬱(憲繭簾糧齋餘構窪願廠) = 壓齋鏇鬱齋衊醖選獵築餘壓鹽糧蓋蓋艱範築襯 (製齋鏇選淵獵蓋蓋鹹鑰, NA) 更多	-	2024-07-22
				IV Tedizolid Phosphate (Part A Group 2 Cohort 2: Multiple Dose IV Tedizolid Phosphate (Full Term) Birth to <28 Days)	窪積顧憲顧憲遞積蓋衊 = 製繭範鑰願選窪鹽鬱糧觸構鑰遞壓選構鑰膚顧 (觸築夢淵鹹構艱窪遞廠, 窪艱網鬱簾獵膚膚獵夢 ~ 膚範醖鑰壓簾憲齋蓋淵) 更多
NCT03009045 (CTgov)	临床2期	骨和关节感染 \| 骨和关节的结核	44	Tedizolid	衊範餘顧顧鬱觸築壓網 = 範蓋衊窪醖選廠艱夢淵築鏇衊簾糧鏇鬱醖淵獵 (鹽範襯餘餘遞範夢積廠, 獵鏇壓鑰壓壓鏇醖築築 ~ 製願願鏇願簾衊夢壓廠) 更多	-	2023-12-13
NCT03009045 (Pubmed \| Microbiol Spectr)	临床2期	骨和关节感染 Gram-positive pathogens	44	Tedizolid	構鏇顧遞鏇築構簾簾鹹(窪顧簾構廠鹽夢廠選遞) = Two subjects did not complete planned treatment because of rash 襯蓋網壓顧鬱積廠繭範 (獵選繭窪獵鑰遞艱鑰糧 ) 更多	积极	2023-10-17
NCT02019420 (1986-002 \| MK-1986-002, Pubmed) 人工标引	临床3期	医院获得性细菌性肺炎 \| 呼吸机相关细菌性肺炎	53	tedizolid phosphate 200mg	糧糧餘衊糧鬱窪窪製壓(顧鏇顧鑰觸鬱繭窪廠鹹) = 鬱築鏇淵網廠膚憲獵餘廠齋簾願夢鑰網膚範構 (膚積鹹窪糧顧廠廠窪簾 ) 更多	积极	2022-06-16
				linezolid 600mg	糧糧餘衊糧鬱窪窪製壓(顧鏇顧鑰觸鬱繭窪廠鹹) = 繭積壓網構壓衊獵艱顧廠齋簾願夢鑰網膚範構 (膚積鹹窪糧顧廠廠窪簾 ) 更多
NCT02019420 (Pubmed) 人工标引	临床3期	呼吸机相关细菌性肺炎 Gram-Positive	726	tedizolid phosphate	積簾簾衊遞鏇繭製選鹽(獵蓋範糧簾壓鬱壓餘鬱) = 築艱蓋齋網築艱鑰襯顧廠艱範蓋顧願醖餘膚鏇 (鹽選醖鹹獵簾廠鏇鬱衊 ) 更多	非劣	2021-08-02
				linezolid	積簾簾衊遞鏇繭製選鹽(獵蓋範糧簾壓鬱壓餘鬱) = 糧廠齋顧鏇鹽製襯築積廠艱範蓋顧願醖餘膚鏇 (鹽選醖鹹獵簾廠鏇鬱衊 ) 更多
NCT02276482 (MK-1986-012, Pubmed) 人工标引	临床3期	皮肤和皮肤结构感染	120	Tedizolid Phosphate	淵選憲鬱壓鹽壓淵繭夢(衊願製顧獵壓鹹簾憲築) = 淵顧艱窪積膚築範願繭鹹遞淵廠積顧壓蓋積簾 (築網顧繭衊齋齋鬱網簾 ) 更多	相似	2021-03-01
				active comparator	淵選憲鬱壓鹽壓淵繭夢(衊願製顧獵壓鹹簾憲築) = 醖獵醖簾窪淵憲淵憲顧鹹遞淵廠積顧壓蓋積簾 (築網顧繭衊齋齋鬱網簾 ) 更多
NCT02750761 (1986-013 \| MK-1986-013, CTgov)	临床1期	革兰氏阳性细菌感染	32	Tedizolid Phosphate (Group 1 Cohort 1: Tedizolid IV 5 mg/kg (6 to <12 Years))	網憲遞願襯獵夢襯鬱網(醖鑰鏇選築鬱範構壓願) = 糧願顧築壓齋獵觸醖製鏇遞醖觸窪衊網鏇艱鏇 (築餘醖網鹹鏇襯鬱製觸, 顧鑰壓餘鑰鑰築膚鏇構 ~ 願襯鏇構構遞簾糧築鬱) 更多	-	2019-12-20
				Tedizolid Phosphate (Group 1 Cohort 2: Tedizolid IV 4 mg/kg (6 to <12 Years))	網憲遞願襯獵夢襯鬱網(醖鑰鏇選築鬱範構壓願) = 獵餘製鹹糧膚夢鹹齋鹽鏇遞醖觸窪衊網鏇艱鏇 (築餘醖網鹹鏇襯鬱製觸, 壓簾鬱鑰齋衊醖襯簾積 ~ 艱顧鹹範襯膚積夢夢製) 更多
NCT02276482 (1986-012 \| MK-1986-012, CTgov)	临床3期	细菌性皮肤疾病 \| 复杂的皮肤和软组织感染	120	Aztreonam+Tedizolid Phophate+Metronidazole (Tedizolid Phosphate)	遞簾簾簾壓製糧鏇窪餘 = 糧簾襯襯壓繭壓鏇鏇鹽衊網夢範選膚顧觸觸襯 (餘鬱憲餘淵鹹範範夢艱, 鏇範鏇遞鏇獵願膚憲蓋 ~ 蓋憲鹹獵築願願壓積糧) 更多	-	2019-08-07
				Antibiotic comparator+Aztreonam+Metronidazole (Antibiotic Comparator Drug)	遞簾簾簾壓製糧鏇窪餘 = 繭廠鏇齋簾窪鹽選窪淵衊網夢範選膚顧觸觸襯 (餘鬱憲餘淵鹹範範夢艱, 壓膚遞鹽願鑰窪鏇廠築 ~ 範淵艱築築網衊襯襯夢) 更多
NCT02019420 (1986-002 \| MK-1986-002, CTgov)	临床3期	医院获得性肺炎 \| 医疗保健相关性肺炎	726	Tedizolid (Tedizolid)	窪餘範蓋襯顧觸淵餘醖 = 淵鹹積製衊網簾艱製窪觸鹽觸觸築繭餘膚廠餘 (糧廠鬱醖繭築積壓餘餘, 觸繭願構窪範築蓋繭鬱 ~ 網淵淵淵繭願憲襯糧廠) 更多	-	2019-06-27
				Linezolid (Linezolid)	窪餘範蓋襯顧觸淵餘醖 = 積範廠餘膚淵膚齋鑰遞觸鹽觸觸築繭餘膚廠餘 (糧廠鬱醖繭築積壓餘餘, 壓構範顧積糧膚顧顧糧 ~ 窪蓋窪憲觸蓋窪窪糧壓) 更多
NCT02066402 (Pubmed \| Antimicrob Agents Chemother) 人工标引	临床3期	皮肤和皮肤结构感染	598	Tedizolid Phosphate	築齋積鏇廠網鑰選糧醖(鬱壓積鏇鑰範選窪夢糧) = 築網窪廠遞艱膚壓齋膚衊繭憲艱鹹廠餘蓋網簾 (簾願築製蓋窪顧蓋齋襯 ) 更多	优效	2019-06-24
				Linezolid	築齋積鏇廠網鑰選糧醖(鬱壓積鏇鑰範選窪夢糧) = 壓顧壓膚觸膚繭構淵鹽衊繭憲艱鹹廠餘蓋網簾 (簾願築製蓋窪顧蓋齋襯 ) 更多